ABT · 10-Q · 2026Q2 · Full report
Medical Device Demand
ABBOTT LABORATORIES · 2026-07-28 · Importance 49 · Surprise 32 · No source text
Medical Devices sales increased 8.0% excluding foreign exchange in the first six months of 2026. Electrophysiology grew 13.0%, primarily from increased ablation catheter and related portfolio sales, while Rhythm Management increased 10.9% due mainly to Aveir leadless pacemakers. Heart Failure sales grew 10.4% on ventricular assist devices and related accessories, and Vascular sales increased 5.0% from endovascular products. Diabetes Care increased 8.2%, driven by continued U.S. and international growth in continuous glucose monitoring systems, whose sales reached $4.1 billion versus $3.6 billion in the prior-year period.
Key facts
- CGM systems sales totaled $4.1 billion in the first six months of 2026 and $3.6 billion in the first six months of 2025, and increased 8.6% excluding the impact of foreign exchange.
- Medical Devices sales were $5,853 million for the three months ended June 30, 2026 versus $5,369 million in the prior year, an increase of 9.0% (1.1% FX impact, 7.9% excl. FX).
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +2.1% | CGM systems sales totaled $4.1 billion in the first six months of 2026 and $3.6 billion in the first six months of 2025, and increased… |
| revenue | positive | realized | +2.0% | Medical Devices sales were $5,853 million for the three months ended June 30, 2026 versus $5,369 million in the prior year, an increase of… |